Training Experience Required
- MD and/or PhD
Institut Curie dates back to 1909, when Marie Curie implemented in the heart of Paris her bench-to-bedside vision of a research-care continuum. A leading player in the fight against cancer, the internationally renowned Institut Curie combines a Research Center and a Hospital Group that provides care for all types of cancers - including the rarest forms.
By embracing a crossdisciplinary approach, researchers and physicians develop together cancer-focused basic, translational and clinical research to discover more effective treatments and improve care for patients.
Institut Curie (IC) is a national and international expert center for Uveal melanoma (UM). The international leading position of IC in the medical care of UM patients is due to the excellence of a multidisciplinary team gathering unique expertise in ophthalmology, radiotherapy (brachytherapy, and proton beam radiotherapy at the Orsay site), pathology, tumor cytogenetics, radiology, liver surgery and medical oncology. IC recruits more than 300 new untreated patients per year, and manages 60 to 80 first line metastatic patients per year. Two weekly multidisciplinary tumor boards (MTB) are dedicated to UM patients, for primary and metastatic disease. Since 1983, IC has built a dedicated database for UM patients, which has been expanded as the French national database since 2008. With more than 5000 new patients registered from 2008 to 2018, this database is unique worldwide. IC is also part of international major clinical trials dedicated to UM patients in the adjuvant and metastatic setting. At the scientific level, IC coordinates the European UM Cure H2020 project, which aims to develop new therapeutic approaches to treat metastatic UM. IC combines scientific expertise in (epi)genetics, immunology, cell signaling, circulating biomarkers, patient-derived xenografts and cell line models to better understand the biology of UM and ultimately
Institut Curie combines a Research Centre and a Hospital Group into a world-class, comprehensive cancer center for multidisciplinary international research and cutting-edge cancer medicine. Institut Curie proposes state-of-the-art facilities both in clinics (including early phase clinical trials, molecular tumor boards, proton therapy, multimodal ocular imaging and ocular surgery) and in the research center (including NGS, patient derived xenografts, single cell platform and experimental radio/protontherapy). Various clinical and translational research projects in UM are ongoing or foreseen and would welcome an ESMO fellow, including secondary effects of irradiation on UM and healthy retina, chromatin organization in UM, circulating biomarkers in UM, response to immunotherapy and combination therapies in vitro and in vivo.